BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol Rep. 2007;9:14-22. [PMID: 17335673 DOI: 10.1007/s11894-008-0016-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Park H, Park JY, Kim SU, Kim do Y, Han KH, Chon CY, Ahn SH. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. World J Gastroenterol. 2013;19:7671-7679. [PMID: 24431895 DOI: 10.3748/wjg.v19.i43.7671] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
2 Gupta S, Altice FL. Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications. J Urban Health 2009;86:263-79. [PMID: 19184447 DOI: 10.1007/s11524-008-9338-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
3 Hoa PT, Huy NT, Thu le T, Nga CN, Nakao K, Eguchi K, Chi NH, Hoang BH, Hirayama K. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2009;53:5134-5140. [PMID: 19770281 DOI: 10.1128/aac.00276-09] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
4 Son CY, Ryu HJ, Lee JM, Ahn SH, Kim DY, Lee MH, Han KH, Chon CY, Park JY. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. Liver Int 2012;32:1179-85. [DOI: 10.1111/j.1478-3231.2012.02793.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
5 Cao B, Liu X, Hou F, Li W, Han Z, Zhang Q, Dai Y, Xu C, Qi H. The haplotype of the MxA gene promoter is associated with hepatitis B virus infection in a Chinese population. Liver Int 2009;29:1383-8. [PMID: 19744071 DOI: 10.1111/j.1478-3231.2009.02053.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kamar N, Milioto O, Alric L, El Kahwaji L, Cointault O, Lavayssière L, Sauné K, Izopet J, Rostaing L. Entecavir Therapy for Adefovir-Resistant Hepatitis B Virus Infection in Kidney and Liver Allograft Recipients. Transplantation 2008;86:611-4. [DOI: 10.1097/tp.0b013e3181806c8c] [Cited by in Crossref: 52] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]